연구성과로 돌아가기

2023 연구자 정보 (143 / 1135)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 ⓘ 교신저자 여부 ⓘ Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Lee, Yong-Sun
(Lee, YS) ⓘ 		Natl Inst Food & Drug Safety Evaluat, Cheongju, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 4.5] ALPHA-1 ANTITRYPSIN/ PROTEINASE 3 IMBALANCE EXERTS PROTEOLYTIC REGULATION ON INTERLEUKIN-32 GAMMA TO PROMOTE NONALCOHOLIC STEATOHEPATITIS ⓘ SCIE ⓘ 4.5 GASTROENTEROLOGY & HEPATOLOGY ⓘ ⓘ
Lee, Youn-Jae
(Lee, YJ) ⓘ 		Inje Univ, Coll Med, Gimhae, South Korea
Inje Univ, Busan Paik Hosp, Coll Med, Dept Internal Med, Busan, South Korea ⓘ 		HGE-5712-2022
Lee, Yoon Jae ⓘ
ⓘ 		[JCR상위 4.5] PROTON PUMP INHIBITOR TREATMENT IS ASSOCIATED WITH A HIGHER MORTALITY IN CIRRHOTIC PATIENTS: A MULTICENTER STUDY
[JCR상위 28.1] Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study ⓘ 		SCIE ⓘ 4.5 GASTROENTEROLOGY & HEPATOLOGY
MEDICINE, GENERAL & INTERNAL ⓘ 		AHNSH@yuhs.ac;limys@amc.seoul.kr; ⓘ
Lim, Seng Gee
(Lim, SG) ⓘ 		Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore
Natl Univ Singapore Hosp, Div Gastroenterol & Hepatol, Singapore, Singapore
Natl Univ Hlth Syst, Singapore, Singapore ⓘ 		AAD-9040-2020
LIM, Seng ⓘ 		0000-0003-0994-4932
Lim, Seng Gee ⓘ 		[JCR상위 4.5] Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis
[JCR상위 4.5] INITIAL EXPLORATION OF HEPATITIS B SURFACE ANTIGEN ( HBsAg) BLIPS FOLLOWING BEPIROVIRSEN TREATMENT: A POST HOC ANALYSIS OF THE B- CLEAR STUDY
[JCR상위 1.7] Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report ⓘ 		SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ daniel_huang@nus.edu.sg;nobuharu.tamaki@gmail.com;psyoung0419@gmail.com;kurosaki@musashino.jrc.or.jp;h.marusawa@osaka-med.jrc.or.jp;matoshi@matsuyama.jrc.or.jp;Masachan44@gmail.com;laboratory@matsue.jrc.or.jp;kobashi0584@gmail.com;furuta-k@masuda.jrc.or.jp;izumi012@musashino.jrc.or.jp;beomkkim@yuhs.ac;sinndhn@hanmail.net;
robert.c.elston@gsk.com; ⓘ
Lim, Tae Seop
(Lim, TS) ⓘ 		Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea ⓘ
ⓘ 		0000-0002-4578-8685
LIM, TAE SEOP ⓘ 		[JCR상위 4.5] Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis ⓘ SCIE ⓘ 4.5 GASTROENTEROLOGY & HEPATOLOGY ⓘ daniel_huang@nus.edu.sg;nobuharu.tamaki@gmail.com;psyoung0419@gmail.com;kurosaki@musashino.jrc.or.jp;h.marusawa@osaka-med.jrc.or.jp;matoshi@matsuyama.jrc.or.jp;Masachan44@gmail.com;laboratory@matsue.jrc.or.jp;kobashi0584@gmail.com;furuta-k@masuda.jrc.or.jp;izumi012@musashino.jrc.or.jp;beomkkim@yuhs.ac;sinndhn@hanmail.net; ⓘ
Lim, Young-Suk
(Lim, YS) ⓘ 		제1저자 Univ Ulsan, Dept Gastroenterol, Asan Med Ctr, Coll Med, Seoul, South Korea
Univ Ulsan, Ctr Liver, Asan Med Ctr, Coll Med, Seoul, South Korea
Univ Hong Kong, State Key Lab Liver Res, Hong Kong, Peoples R China
Univ Ulsan, Asan Med Ctr, Dept Internal Med, Coll Med, Seoul, South Korea
Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol,Liver Ctr, Seoul, South Korea ⓘ 		AFQ-5165-2022
Lim, Young-Suk ⓘ
ⓘ 		[JCR상위 4.5] PHASE 1b/2a STUDY OF HETEROLOGOUS ChAdOx1-HBV/MVA-HBV THERAPEUTIC VACCINATION (VTP-300) COMBINED WITH LOW-DOSE NIVOLUMAB (LDN) IN VIRALLY-SUPPRESSED PATIENTS WITH CHB ON NUCLEOS(T)IDE ANALOGUES
[JCR상위 1.7] Safety and efficacy of VIR-2218 with or without pegylated interferon alfa in virally-suppressed participants with chronic hepatitis B virus infection: post-treatment follow-up
[JCR상위 8.7] Personalized Antiviral Drug Selection in Patients With Chronic Hepatitis B Using a Machine Learning Model: A Multinational Study
[JCR상위 28.1] Efficacy and safety of sofosbuvir-velpatasvir and sofosbuvir-velpatasvir-voxilaprevir for hepatitis C in Korea: a Phase 3b study ⓘ 		SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY
MEDICINE, GENERAL & INTERNAL ⓘ 		mfyuen@hku.hk;
mhhur@snu.ac.kr;alsrud627@snu.ac.kr;terryfungyip@gmail.com;e580306@ms31.hinet.net;vital@snu.ac.kr;dr.choi85@gmail.com;KSUKOREA@yuhs.ac;limys@amc.seoul.kr;psyoung0419@gmail.com;wonglaihung@mect.cuhk.edu.hk;sinndhn@gmail.com;jyj412@hanmail.net;sekim@hallym.or.kr;cypeng@mail.cmuh.org.tw;drshp@khu.ac.kr;5137ccy@gmail.com;hwiyoung@gmail.com;amelia86@naver.com;gandorie@gmail.com;noshin@hanyang.ac.kr;mseileen80@hanyang.ac.kr;sonjh@hanyang.ac.kr;dr486@eulji.ac.kr;jshim3927@gmail.com;jeongsw@schmc.ac.kr;choyk2004.cho@samsung.com;hskim@kdh.or.kr;mjjang2014@naver.com;yoonjun@snu.ac.kr;yoonjh@snu.ac.kr;pindra@empal.com;
AHNSH@yuhs.ac;limys@amc.seoul.kr; ⓘ
Lin, Chuan-Hao
(Lin, CH) ⓘ 		Childrens Hosp Los Angeles, Los Angeles, CA USA ⓘ AAH-6563-2019
Lin, Chuan-Hao ⓘ
ⓘ 		[JCR상위 4.5] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE ( TAF) AT 2 YEARS IN CHILDREN AND ADOLESCENTS WITH CHRONIC HEPATITIS B ( CHB) ⓘ SCIE ⓘ 4.5 GASTROENTEROLOGY & HEPATOLOGY ⓘ ⓘ
Liu, Yang
(Liu, Y) ⓘ 		Gilead Sci Inc, Foster City, CA USA ⓘ
ⓘ
ⓘ 		[JCR상위 4.5] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE ( TAF) AT 2 YEARS IN CHILDREN AND ADOLESCENTS WITH CHRONIC HEPATITIS B ( CHB) ⓘ SCIE ⓘ 4.5 GASTROENTEROLOGY & HEPATOLOGY ⓘ ⓘ
Lo, Gin-Ho
(Lo, GH) ⓘ 		E Da Hosp, Kaohsiung, Taiwan ⓘ
ⓘ
ⓘ 		[JCR상위 4.5] PHASE 1b/2a STUDY OF HETEROLOGOUS ChAdOx1-HBV/MVA-HBV THERAPEUTIC VACCINATION (VTP-300) COMBINED WITH LOW-DOSE NIVOLUMAB (LDN) IN VIRALLY-SUPPRESSED PATIENTS WITH CHB ON NUCLEOS(T)IDE ANALOGUES ⓘ SCIE ⓘ 4.5 GASTROENTEROLOGY & HEPATOLOGY ⓘ ⓘ
Lukic, Tamara
(Lukic, T) ⓘ 		GSK, Dubai, U Arab Emirates ⓘ
ⓘ
ⓘ 		[JCR상위 4.5] INITIAL EXPLORATION OF HEPATITIS B SURFACE ANTIGEN ( HBsAg) BLIPS FOLLOWING BEPIROVIRSEN TREATMENT: A POST HOC ANALYSIS OF THE B- CLEAR STUDY ⓘ SCIE ⓘ 4.5 GASTROENTEROLOGY & HEPATOLOGY ⓘ ⓘ
Ma, Hwan
(Ma, H) ⓘ 		Chungbuk Natl Univ, Cheongju, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 4.5] ALPHA-1 ANTITRYPSIN/ PROTEINASE 3 IMBALANCE EXERTS PROTEOLYTIC REGULATION ON INTERLEUKIN-32 GAMMA TO PROMOTE NONALCOHOLIC STEATOHEPATITIS ⓘ SCIE ⓘ 4.5 GASTROENTEROLOGY & HEPATOLOGY ⓘ ⓘ
Marusawa, Hiroyuki
(Marusawa, H) ⓘ 		Osaka Red Cross Hosp, Dept Gastroenterol & Hepatol, Osaka, Japan ⓘ
ⓘ
ⓘ 		[JCR상위 4.5] Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis ⓘ SCIE ⓘ 4.5 GASTROENTEROLOGY & HEPATOLOGY ⓘ daniel_huang@nus.edu.sg;nobuharu.tamaki@gmail.com;psyoung0419@gmail.com;kurosaki@musashino.jrc.or.jp;h.marusawa@osaka-med.jrc.or.jp;matoshi@matsuyama.jrc.or.jp;Masachan44@gmail.com;laboratory@matsue.jrc.or.jp;kobashi0584@gmail.com;furuta-k@masuda.jrc.or.jp;izumi012@musashino.jrc.or.jp;beomkkim@yuhs.ac;sinndhn@hanmail.net; ⓘ
Mashiba, Toshie
(Mashiba, T) ⓘ 		Matsuyama Red Cross Hosp, Ctr Liver Biliary Pancreat Dis, Matsuyama, Ehime, Japan ⓘ
ⓘ
ⓘ 		[JCR상위 4.5] Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis ⓘ SCIE ⓘ 4.5 GASTROENTEROLOGY & HEPATOLOGY ⓘ daniel_huang@nus.edu.sg;nobuharu.tamaki@gmail.com;psyoung0419@gmail.com;kurosaki@musashino.jrc.or.jp;h.marusawa@osaka-med.jrc.or.jp;matoshi@matsuyama.jrc.or.jp;Masachan44@gmail.com;laboratory@matsue.jrc.or.jp;kobashi0584@gmail.com;furuta-k@masuda.jrc.or.jp;izumi012@musashino.jrc.or.jp;beomkkim@yuhs.ac;sinndhn@hanmail.net; ⓘ
Mehta, Reena
(Mehta, R) ⓘ 		Vaccitech Plc, Clin Operat, Oxford, England ⓘ LFU-3952-2024
Mehta, Reena ⓘ
ⓘ 		[JCR상위 4.5] PHASE 1b/2a STUDY OF HETEROLOGOUS ChAdOx1-HBV/MVA-HBV THERAPEUTIC VACCINATION (VTP-300) COMBINED WITH LOW-DOSE NIVOLUMAB (LDN) IN VIRALLY-SUPPRESSED PATIENTS WITH CHB ON NUCLEOS(T)IDE ANALOGUES ⓘ SCIE ⓘ 4.5 GASTROENTEROLOGY & HEPATOLOGY ⓘ ⓘ
Mohamed, Rosmawati
(Mohamed, R) ⓘ 		Univ Malaya, Med Ctr, Pusat Perubatan Univ Malaya, Kuala Lumpur, Malaysia ⓘ
ⓘ
ⓘ 		[JCR상위 4.5] INITIAL EXPLORATION OF HEPATITIS B SURFACE ANTIGEN ( HBsAg) BLIPS FOLLOWING BEPIROVIRSEN TREATMENT: A POST HOC ANALYSIS OF THE B- CLEAR STUDY ⓘ SCIE ⓘ 4.5 GASTROENTEROLOGY & HEPATOLOGY ⓘ ⓘ
Moon, Sang Yi
(Moon, SY) ⓘ 		Dong A Univ, Coll Med, Busan, South Korea
Dong A Univ, Dept Internal Med, Coll Med, Busan, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 4.5] PROPOSAL OF A NOVEL SEROLOGICAL ALGORITHM COMBINING A FIBROSIS INDEX BASED ON FOUR AND SERUM MAC-2 BINDING PROTEIN GLYCOSYLATION ISOMER FOR ADVANCED FIBROSIS IN NON-ALCOHOLIC FATTY LIVER DISEASE
[JCR상위 1.7] The role of M2BPGi in screening for advanced hepatic fibrosis in diabetic patients
[JCR상위 1.7] The role of M2BPGi for screening of advanced hepatic fibrosis in elderly patients
[JCR상위 1.7] Fibrosis-4 and M2BPGi combination screening algorithm for screening advanced hepatic fibrosis in diabetes is cost-effective
[JCR상위 1.7] Diagnostic efficacy of Mac-2 binding protein glycosylation isomer for predicting liver fibrosis in patients with metabolic associated fatty liver disease: multicenter cohort study ⓘ 		SCIE ⓘ 1.7 GASTROENTEROLOGY & HEPATOLOGY ⓘ noshin@hanyang.ac.kr;
gongori1004@gmail.com; ⓘ
페이지 이동: